Audubon-based Globus Medical has announced its acquisition of California life sciences company Nevro Corp. for $250 million ...

In a report released today, Matt Miksic from Barclays maintained a Buy rating on Globus Medical (GMED – Research Report), with a price target ...

In a report released today, David Saxon from Needham maintained a Hold rating on Globus Medical (GMED – Research Report). The company’s shares ...

On a stand-alone basis, Globus Medical (GMED) reaffirms guidance for 2025 net sales of $2.66B to $2.69B and fully diluted non-GAAP earnings per ...

Globus Medical (GMED) has agreed to buy Nevro (NVRO) through an all-cash deal valued at around $250M. Read more here.

Request To Download Free Sample of This Strategic Report @ Driving Forces Behind Growth: The exponential growth of the North America medical implant market is propelled by several key drivers.

Request To Download Free Sample of This Strategic Report @ Driving Forces of Growth: The unprecedented growth of the medical implant market is propelled by several key factors. Firstly, the aging ...

Globus Medical, Inc. has a 12 month low of $49.33 and a 12 month high of $94.93. The stock has a fifty day simple moving average of $85.85 and a two-hundred day simple moving average of $77.36.

Globus Medical, Inc. (NYSE:GMED – Free Report) – Stock analysts at Roth Capital dropped their FY2024 earnings per share (EPS) estimates for shares of Globus Medical in a research note issued ...

AUDUBON, Pa., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full-year ...